Infliximab (Remsima SC®), in combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in:
– Adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate.
– Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||04/03/2020|
|Rapid review completed||24/03/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.